Korea Q2 Roundup: New Drugs Drive Growth, First-Line Lazertinib Approval

New Indications For U-Turned Assets, 'Glocalization'

 
• By Jung Won Shin

Aside from a mixed bag of second-quarter earnings, the latest developments in the Korean pharma industry include Hanmi’s search for new indications for u-turned assets and the approval of Yuhan’s lazertinib as a first-line treatment for NSCLC.

Quarterly report
Hanmi, SK Biopharm Seek New Road Maps For Growth As Q2 results announced • Source: Shutterstock

More from South Korea

More from Focus On Asia